DK1416965T3 - Assayfremgangsmåde til Alzheimers sygdom - Google Patents
Assayfremgangsmåde til Alzheimers sygdomInfo
- Publication number
- DK1416965T3 DK1416965T3 DK02766022T DK02766022T DK1416965T3 DK 1416965 T3 DK1416965 T3 DK 1416965T3 DK 02766022 T DK02766022 T DK 02766022T DK 02766022 T DK02766022 T DK 02766022T DK 1416965 T3 DK1416965 T3 DK 1416965T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- alzheimer
- beta
- assay procedure
- preclinical
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31322401P | 2001-08-17 | 2001-08-17 | |
| US31322101P | 2001-08-17 | 2001-08-17 | |
| US33498701P | 2001-10-23 | 2001-10-23 | |
| PCT/US2002/026321 WO2003015617A2 (en) | 2001-08-17 | 2002-08-16 | Assay method for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1416965T3 true DK1416965T3 (da) | 2008-05-05 |
Family
ID=27405654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02766022T DK1416965T3 (da) | 2001-08-17 | 2002-08-16 | Assayfremgangsmåde til Alzheimers sygdom |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1416965B8 (da) |
| JP (2) | JP4511830B2 (da) |
| AT (1) | ATE381346T1 (da) |
| CA (1) | CA2457145C (da) |
| CY (1) | CY1107901T1 (da) |
| DE (1) | DE60224200T2 (da) |
| DK (1) | DK1416965T3 (da) |
| ES (1) | ES2295401T3 (da) |
| PT (1) | PT1416965E (da) |
| WO (1) | WO2003015617A2 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| PT1944040E (pt) | 2001-08-17 | 2012-10-31 | Univ Washington | Método de avaliação para a doença de alzheimer |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| ATE468886T1 (de) | 2003-02-10 | 2010-06-15 | Applied Molecular Evolution | Abeta-bindende moleküle |
| EP1480041A1 (en) * | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
| GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| DK2121754T3 (da) | 2007-01-18 | 2015-02-23 | Lilly Co Eli | Pegyleret amyloid beta fab |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| WO2010093001A1 (ja) * | 2009-02-13 | 2010-08-19 | 国立大学法人大阪大学 | アルツハイマー病の診断方法および診断薬 |
| BR112012014060B8 (pt) | 2009-12-11 | 2021-07-27 | Araclon Biotech Sl | método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| IL245703B (en) * | 2013-11-20 | 2022-07-01 | Univ Iowa Res Found | Methods and compositions for treating amyloid deposits |
| CN109187981A (zh) * | 2018-08-01 | 2019-01-11 | 万东山 | 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用 |
| KR102496845B1 (ko) * | 2018-08-08 | 2023-02-08 | 서울대학교산학협력단 | 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334337D1 (de) * | 1992-10-26 | 2010-08-26 | Elan Pharm Inc | Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP) |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6730778B2 (en) * | 1997-12-19 | 2004-05-04 | Pharmacia And Upjohn Company | Human sel-10 polypeptides and polynucleotides that encode them |
| DE1257584T1 (de) * | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
-
2002
- 2002-08-16 PT PT02766022T patent/PT1416965E/pt unknown
- 2002-08-16 CA CA2457145A patent/CA2457145C/en not_active Expired - Fee Related
- 2002-08-16 ES ES02766022T patent/ES2295401T3/es not_active Expired - Lifetime
- 2002-08-16 JP JP2003520382A patent/JP4511830B2/ja not_active Expired - Lifetime
- 2002-08-16 DE DE60224200T patent/DE60224200T2/de not_active Expired - Lifetime
- 2002-08-16 AT AT02766022T patent/ATE381346T1/de active
- 2002-08-16 DK DK02766022T patent/DK1416965T3/da active
- 2002-08-16 EP EP02766022A patent/EP1416965B8/en not_active Expired - Lifetime
- 2002-08-16 WO PCT/US2002/026321 patent/WO2003015617A2/en not_active Ceased
-
2008
- 2008-03-07 CY CY20081100267T patent/CY1107901T1/el unknown
-
2009
- 2009-09-09 JP JP2009208372A patent/JP5162553B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2457145C (en) | 2010-12-21 |
| HK1061960A1 (en) | 2004-10-15 |
| EP1416965A2 (en) | 2004-05-12 |
| EP1416965B1 (en) | 2007-12-19 |
| DE60224200T2 (de) | 2008-07-10 |
| PT1416965E (pt) | 2008-04-01 |
| ATE381346T1 (de) | 2008-01-15 |
| EP1416965B8 (en) | 2008-02-13 |
| DE60224200D1 (de) | 2008-01-31 |
| ES2295401T3 (es) | 2008-04-16 |
| CY1107901T1 (el) | 2013-09-04 |
| CA2457145A1 (en) | 2003-02-27 |
| WO2003015617A2 (en) | 2003-02-27 |
| JP2010044078A (ja) | 2010-02-25 |
| WO2003015617A3 (en) | 2004-01-29 |
| JP2004538477A (ja) | 2004-12-24 |
| JP5162553B2 (ja) | 2013-03-13 |
| EP1416965A4 (en) | 2005-11-02 |
| JP4511830B2 (ja) | 2010-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107901T1 (el) | Μεθοδος προσδιορισμου για ασθενεια alzheimer | |
| EP1944040A3 (en) | Assay method for Alzheimer's disease | |
| EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
| DE60235746D1 (de) | Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation | |
| DK1351707T3 (da) | Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyser | |
| ATE280783T1 (de) | Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis | |
| DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| WO2000018954A3 (en) | Use of pex in the treatment of metabolic bone diseases | |
| ATE244299T1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
| ATE318328T1 (de) | Diagnostika und therapeutika für osteoporose | |
| EP1421104A4 (en) | HUMANE ZONA PELLUCIDA PROTEINS AND METHOD FOR THEIR USE IN THE DIAGNOSIS OF MALE INFERENCE | |
| DK1353948T3 (da) | Oplöselige biologiske analoge til bata-amyloidpeptid | |
| PT998556E (pt) | Diagnostico e tratamento de doencas utilizando anticorpos antivbeta do receptor de celulas t ou peptidos que sao reconhecidos pelos referidos anticorpos e proteina reguladora da secrecao endocrina 1 (esrp1) | |
| BRPI0407213A (pt) | Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados | |
| WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
| AU2003224120A1 (en) | Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases | |
| DK1406927T3 (da) | Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose | |
| WO2004038411A3 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
| DK1379882T3 (da) | Diagnostisk og terapeutisk anvendelse af et nuclearbegrænset protein til Alzheimers syge og beslægtede neurodegenerative forstyrrelser | |
| AU2002366555A1 (en) | Diagnostic for early stage alzheimer's disease | |
| DE50214523D1 (de) | Nukleotidträger zur diagnose und therapie oraler erkrankungen | |
| DE60303360D1 (de) | Diagnostische und therapeutische verwendung des caps | |
| AU2003215667A1 (en) | Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases | |
| WO2002088345A3 (en) | Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene | |
| FR2837284B1 (fr) | Methode de diagnostic serologique in vitro des endocardites infectieuses |